NasdaqGS:FPRX

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of innovative protein therapeutics.


Snowflake Analysis

Excellent balance sheet and fair value.

Share Price & News

How has Five Prime Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: FPRX's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

12.6%

FPRX

-3.9%

US Biotechs

1.3%

US Market


1 Year Return

20.7%

FPRX

27.2%

US Biotechs

14.9%

US Market

Return vs Industry: FPRX underperformed the US Biotechs industry which returned 24.5% over the past year.

Return vs Market: FPRX exceeded the US Market which returned 12.5% over the past year.


Shareholder returns

FPRXIndustryMarket
7 Day12.6%-3.9%1.3%
30 Day-1.0%-3.5%4.7%
90 Day82.0%7.4%17.1%
1 Year20.7%20.7%28.5%27.2%17.3%14.9%
3 Year-79.7%-79.7%26.2%22.0%38.9%29.9%
5 Year-68.9%-68.9%-4.2%-9.7%71.3%52.8%

Price Volatility Vs. Market

How volatile is Five Prime Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Five Prime Therapeutics undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: FPRX ($5.9) is trading below our estimate of fair value ($28.66)

Significantly Below Fair Value: FPRX is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: FPRX is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: FPRX is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate FPRX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: FPRX is good value based on its PB Ratio (1.5x) compared to the US Biotechs industry average (3.3x).


Next Steps

Future Growth

How is Five Prime Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

9.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: FPRX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: FPRX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: FPRX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: FPRX's revenue (31% per year) is forecast to grow faster than the US market (9.3% per year).

High Growth Revenue: FPRX's revenue (31% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if FPRX's Return on Equity is forecast to be high in 3 years time


Next Steps

  • Explore growth companies in the Pharmaceuticals & Biotech industry.

Past Performance

How has Five Prime Therapeutics performed over the past 5 years?

-42.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: FPRX is currently unprofitable.

Growing Profit Margin: FPRX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: FPRX is unprofitable, and losses have increased over the past 5 years at a rate of 42.2% per year.

Accelerating Growth: Unable to compare FPRX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: FPRX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-22.5%).


Return on Equity

High ROE: FPRX has a negative Return on Equity (-90.63%), as it is currently unprofitable.


Next Steps

Financial Health

How is Five Prime Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: FPRX's short term assets ($150.3M) exceed its short term liabilities ($19.2M).

Long Term Liabilities: FPRX's short term assets ($150.3M) exceed its long term liabilities ($49.2M).


Debt to Equity History and Analysis

Debt Level: FPRX is debt free.

Reducing Debt: FPRX has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: FPRX has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if FPRX has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Five Prime Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate FPRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate FPRX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if FPRX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if FPRX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of FPRX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.1yrs

Average management tenure


CEO

Tom Civik (51 yo)

0.33

Tenure

Mr. Thomas Civik, also known as Tom, serves as President and Chief Executive Officer and Director at Five Prime Therapeutics, Inc. since April 13, 2020. Mr. Civik served as a Chief Commercial Officer of Fo ...


Leadership Team

NamePositionTenureCompensationOwnership
Helen Collins
Executive VP & Chief Medical Officer3.42yrsUS$1.60m0.18%
$ 383.4k
Francis Sarena
Chief Strategy Officer & Secretary9.67yrsUS$1.51m0.61%
$ 1.3m
Thomas Civik
President0.33yrno data0.21%
$ 442.5k
David Smith
Executive VP & CFO1.75yrsUS$2.43m0.18%
$ 374.0k
David White
Principal Accounting Officer1.5yrsno data0.12%
$ 253.4k
Martin Forrest
Vice President of Investor Relations & Corporate Communicationsno datano datano data
Nallakkan Arvindan
Senior Vice President of Strategic Technology Operations2.5yrsno datano data

2.1yrs

Average Tenure

56yo

Average Age

Experienced Management: FPRX's management team is considered experienced (2.1 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Thomas Civik
President0.33yrno data0.21%
$ 442.5k
Joseph Goldstein
Member of Scientific Advisory Boardno datano datano data
Daniel Von Hoff
Member of Scientific Advisory Boardno datano datano data
William Ringo
Chairman of the Board1.58yrsUS$1.28m0.028%
$ 59.0k
Peder Jensen
Independent Director9.08yrsUS$132.11kno data
Robert Lefkowitz
Member of Scientific Advisory Boardno datano datano data
Ronald Levy
Member of Scientific Advisory Boardno datano datano data
Franklin Berger
Independent Director9.92yrsUS$115.86k0.014%
$ 29.5k
Drew Pardoll
Member of Scientific Advisory Boardno datano datano data
Arthur Weiss
Member of Scientific Advisory Boardno datano datano data
Garry Nicholson
Independent Director3.25yrsUS$127.74kno data
Kapil Dhingra
Independent Director4.67yrsUS$113.36kno data

4.0yrs

Average Tenure

71yo

Average Age

Experienced Board: FPRX's board of directors are considered experienced (4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Five Prime Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Five Prime Therapeutics, Inc.
  • Ticker: FPRX
  • Exchange: NasdaqGS
  • Founded: 2001
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$208.517m
  • Shares outstanding: 35.34m
  • Website: https://www.fiveprime.com

Number of Employees


Location

  • Five Prime Therapeutics, Inc.
  • 111 Oyster Point Boulevard
  • South San Francisco
  • California
  • 94080
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
FPRXNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDSep 2013
5P8DB (Deutsche Boerse AG)YesCommon StockDEEURSep 2013

Biography

Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of innovative protein therapeutics. The company’s product candidates comprise Bemarituzumab, ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/08/03 23:36
End of Day Share Price2020/08/03 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.